# US 4,515,777 A · Vaccines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 4,515,777 A
- Document ID: US4515777A
- Status: Granted
- Kind: A
- Application number: 06/440,640
- Filed: 1982-11-10
- Granted: 1985-05-07
- Earliest claimed: 1978-12-20
- Assignees: Gist-Brocades N.V.
- Inventors: Peter Apontoweil; Manfred M. Krasselt
- Web page: https://patentgrep.com/patent/US4515777A

## CPC

- A61K 39/15: Reoviridae, e.g. calf diarrhea virus
- A61K 39/12: Viral antigens
- A61K 39/17: Newcastle disease virus
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/552: {Veterinary vaccine}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/70: {Multivalent vaccine}
- C12N 2720/12034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/18134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y10S 424/816: Viral vaccine for avian species, e.g. poultry or other birds
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

Vaccines derived from aviair reo-virus to combat aberations of the skeleton such as rachitis--like symptoms, diarrhoea and growth inhibition, a process for their preparation as well as combined, inactivated vaccines, ready for administration and active against at least Newcastle disease and aberations of the skeleton, diarrhoea and growth inhibition and process for the preparation of such vaccine. The combined vaccine is prepared by addition of a Newcastle disease virus (NDV) containing liquid obtained by cultivation of a NDV, followed by inactivation of this liquid and optionally homogenizing it, together with a reo-virus containing liquid obtained by cultivation of a reo-virus, followed by inactivation of this liquid and optionally homogenizing it to an oily phase containing as essential components at least one of the components selected from the group consisting of light paraffinic mineral oils, plant oils and naphthenic mineral oils and one or more emulsifiers such as nonionic surface-active compounds derived from alkylene oxide and/or hexahydric alcohols and/or higher natural fatty acids such as esters or ester-ethers, optionally followed by homogenizing and/or addition of a preservative.

## Claims

### Claim 1

In a combined inactivated vaccine ready for use against symptoms in poultry caused by avian reo viruses and by Newcastle disease virus (NDV), characterized in that the vaccine contains an inactivated Newcastle disease virus containing liquid having a titre of 10.sup.9.8 -10.sup.10.5 EID.sub.50 /ml, and an inactivated reo virus containing liquid derived from reo virus strain LZ 671 deposited with Collection d'Institut Pasteur, Paris under No. 1.092 having a titre of 10.sup.5.5 -10.sup.7.5 EID.sub.50 /ml, the improvement consisting essentially of the volume ratio between the Newcastle disease virus containing liquid and the reo virus containing liquid being from 3:4 to 5:1, and wherein an oil phase with essential components selected from the group consisting of at least light paraffinic mineral oils (FDA quality), plant oils and naphthenic mineral oils and at least one emulsifier in the form of non-ionic surface-active compounds derived from esters or esterethers of alkylene oxide and/or hexahydric alcohols and/or higher natural fatty acids of 10 to 20 carbon atoms, the volume ratio between the aqueous phase formed by both virus liquids and the oil phase being from 7:13 to 3:7.

### Claim 2 (depends on 1)

Inactivated vaccine of claim 1 wherein the oily phase contains 2 to 20% by weight of an emulsifier calculated on the oily phase weight.

### Claim 3 (depends on 2)

The vaccine of claim 2 wherein the emulsifier is 2 to 15% by weight of Arlacel A or Arlacel 80 or Span 80 or 0.2 to 4% of Tween 80.

### Claim 4 (depends on 1)

The combined vaccine of claim 1 wherein the ratio is about 3:2.

### Claim 5 (depends on 1)

Process for preventing symptoms caused by Newcastle disease and by aviair reo-virus in poultry comprising vaccinating the poultry with the vaccine of claim 1.